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Abstract
Vertebrates employ V(D)J recombination to generate diversity for an adaptive immune response.
Born of a transposon, V(D)J recombination could conceivably cause more trouble than it's worth.
However, of the two steps required for transposon mobility (excision and integration) this particular
transposon's integration step appears mostly blocked in cells. The employment of a transposon as
raw material to develop adaptive immunity was thus a less-risky choice than it might have been…
but is it completely risk-free?
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1. Introduction
V(D)J recombination assembles the immune system's antigen specific receptors
(immunoglobulins and T cell receptors)(see e.g. [1] for a general review). In the first step,
lymphocyte specific recombination activating genes 1 and 2 (RAG1 and RAG2) introduce a
pair of chromosome breaks between recombination targeting signals (RS) and receptor coding
DNA. In typical RS arrangements this excises a fragment from the receptor locus with RS ends
(signal ends) (Figure 1). “Host” repair machinery (nonhomologous end joining, or NHEJ), then
resolves these breaks. Still poorly understood interactions between RAG1/RAG2 and NHEJ
help ensure pair-wise resolution of receptor coding ends results in assembly of a mature
receptor gene.
In vitro studies have shown V(D)J recombination has clear origins in transposition. Most
importantly, RAG1- RAG2 cleave and join DNA strands by direct (or one-step)
transesterification [2]. A donor DNA strand 3′OH terminus is used as a nucleophile to attack
a phosphodiester bond in a target DNA strand, breaking the bond 5′ of the phosphate attacked
in the target strand and replacing it with a new bond, between the donor strand's 3′ end and the
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targeted phosphate. Initially, RAG-mediated one-step transesterification is critical for making
the chromosome breaks that flank the RS pair. A nick adjacent to an RS generates a donor 3′
OH, and this 3′OH attacks the immediately opposite phosphodiester bond. This
transesterification generates a double strand break between the RS and receptor coding DNA,
where the RS end is blunt ended and the coding end possesses a characteristic hairpin terminus.
Cleavage requires recognition of a pair of RS and both RS are cleaved at the same time, resulting
in excision of a linear fragment with RS ends (signal end fragment). In sum, initial breakage
of DNA (e.g. at receptor loci) is analogous to transposon excision; indeed, the same end
structures (blunt RS ends, hairpin terminated flanks) are generated when the hAT family
transposons excise from their host genome [3].
RAG proteins can remain bound to the excised signal end fragment in vitro and continue to
perform direct transesterification, but now using the signal end 3′OH as a donor. The next
transesterification step can target the recently generated hairpin-coding end, essentially
reversing the initial cleavage reaction [4]. The products of these reactions are termed open-
and-shut or hybrid junctions. Alternatively, RAG1/RAG2 bound signal ends can direct strand
transfer of the excised element into a “foreign” DNA target in a process equivalent to the
integration step in transposition (Figure 2a) [5,6]. Strand transfers are often concerted such that
both RS ends attack the same target duplex, but with each of the RS ends attacking bonds in
opposite strands of the target 4-5 bp apart. As a result the excised “transposon” is integrated
into the target and flanked by 4-5 nucleotide gaps. Gap repair generates a 4-5 direct repeat of
flanking target DNA, or a target site duplication, that is considered a signature of transposition
integrations.
At least in vitro, therefore, RAG1 and RAG 2 mediate the excision and integration of a RS
bounded DNA fragment through direct transesterifications. V(D)J recombination is a modified
transposon: it was born to be wild. However, while excision of the V(D)J recombination
associated transposon is efficient in lymphoid cells and required for receptor assembly, this
transposon appears tamed in cells by blocking the integration step. A number of mechanisms
for blocking integration in cells have been discussed in other reviews [7-10], most significantly
a C-terminal domain of RAG2 that suppresses transposition in vitro [11-13] and possibly
related aberrant signal end resolutions in cells [14,15].
Nevertheless…
2. It happens: Identification of V(D)J recombination associated transposition
events in cells
Multiple mechanisms direct integration of signal end fragments into chromosomes in cells (see
section 3.1 and 3.2, below). For the purpose of this review we term integrations as transpositions
only if a strong case can be made that the structure of the integration is consistent with RAG-
protein dependent transesterification. Specifically, integrations should be conservative (no lost
sequence or non-templated insertion) both for the donor signal end fragment ends and target
(chromosomal) site, and the target site should be flanked by a 4-5 bp target site duplication.
A screen for HPRT mutations in a human T cell line identified a fragment of the T cell receptor
locus that was integrated within an intron of the HPRT gene [16]. T cell receptor RS ends were
precisely inserted, with no lost sequence relative to the excised fragment (presumptive
transposon). The HPRT intronic DNA flanking the integration site similarly possessed no
deleted sequence or non-templated additions; instead, the insertion site was flanked by a 4 bp
direct repeat of target DNA (TSD). V(D)J recombination associated transposition was
subsequently observed in a reconstituted V(D)J recombination model in yeast [17], between
donor and target episomes in mammalian cells [18], and between an integrated donor
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recombination substrate and genome target in mammalian cells [19]. All four reports identified
a preference for GC rich targets (see also section 4.2), consistent with previous analyses of
RAG mediated integrations in vitro [5,6,20]. Two of these reports identified transpositions in
cells using exclusively full length RAG1 and RAG2 [16,19]. The remaining two reports
identified transpositions using both full length and core RAG constructs, and, together with
the other studies, suggest suppression of transposition by RAG2's C-terminal domain is at best
incomplete [17,18].
Transposition is thus associated with V(D)J recombination in cells. Is it a significant threat to
genome stability - How often does it occur in cells, and when it happens, where does it go?
3. How often?
3.1 How often?
As already noted, excision of the signal end fragment (the putative transposon) is obligatory
for V(D)J recombination; integration is apparently the limiting step. Not all integrations occur
by transposition, though. Assessment of the frequency of V(D)J recombination-associated
transposition thus requires first determining the frequency of integration into host chromosomal
DNA, followed by characterization of integrations as “transposition” (integration by
transesterification) or not based on the criteria described above. Finally, transposition has only
loosely defined target site preferences (see section 4) [5,6,20], thus the most useful estimations
of transposition frequency require the ability to recovery integration events regardless of target
site (i.e. a genome-wide screen).
Our group employed an integrated artificial substrate as the source of the putative transposon
(signal end fragment) and a virally transformed pre-B cell line as host to address this issue
[19]. We induced V(D)J recombination to release the signal end fragment (excision) and
determined it integrates back into the genome once every 1.3×104 excisions (V(D)J
recombinations). Notably, subsequent studies from both the Nadel [21] and Schlissel [14]
groups also scored chromosomal integrations of signal end fragments excised from the T cell
receptor locus during normal mouse development, a more biologically relevant model.
Consistent with our study, both groups determined this event was surprisingly frequent: for
example, the Schlissel group assessed its frequency as between 10-3 to 10-5.
Our group then characterized the structure of signal end fragment integrations to determine if
they occurred by transposition. Our initial report isolated and characterized 21 integrations;
we summarize here an expanded data set that includes an additional 23 integrations isolated
and characterized using the same experimental model (Table 1). We observed transposition in
25% (11/44; 95% C.I. ∼15%-40%) of integrations (Table 2). Taking into account the frequency
of all signal end fragment integrations (discussed above), we observed a transposition about
once every 50,000 V(D)J recombinations (95% confidence interval; ∼ 1/30,000 to 1/90,000).
This frequency predicts the V(D)J recombinations required for the daily lymphocyte output of
an adult human would be associated with about 10,000 transposon integrations [19].
3.2 Transposition vs. other integration mechanisms
Integrations of the candidate transposon are generally consistent with one of three mechanisms:
transposition, intermolecular recombination, or end donation (Figure 2).
The primary pathway for integration of the candidate transposon is probably not transposition,
but rather intermolecular recombination [14,21] (reviewed in [22,23]). Intermolecular
recombinations possess a characteristic signal junction, where one of the signal ends of the
integrating fragment is precisely fused to a genomic RS. The other RS is fused to DNA
immediately flanking the genomic RS (pseudo-hybrid junction) [19,21,24,25] (Figure 2b,Table
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1). As characterized in detail by the Nadel group [21], such events are probably mediated by
intermolecular recombination (or recombination in trans): a V(D)J recombination between the
extrachromosomal RS in the signal end fragment and the genomic RS. Association of
intermolecular recombinations with lymphoid malignancy has been well established [24,26];
in this regard, we note a non-Ig locus intermolecular recombination in our data set targeted the
first intron of Pax5 (Table 1), a site rearranged in a large fraction of in acute lymphoblastic
leukemias [27].
Other integrations (classified as End donations) are characterized primarily by a lack of the
previously described distinguishing features (target site duplications and signal junctions;
Table 1, Figure 2c). In these events the RAG-bound signal end fragment did not actively
participate in breaking the chromosomal target site. Instead, the integrating fragment simply
“donated an end” to participate in NHEJ to an independently generated DSB. Consistent with
this model integration structures more commonly have deletions of signal ends (Table 2).
Nevertheless, these events can often still be linked to V(D)J recombination. In our study, at
least one and often both signal ends were usually (14/18) fused to DNA that previously flanked
a genomic RS (coding end) to generate a hybrid junction (Figure 2c). Hybrid junctions can be
mediated by either NHEJ or RAG mediated transesterification [4] (see also section 1, section
3.2). An interesting (though unlikely) [15,21,28] possibility is that at least a portion of these
events (those without deletions from signal ends) could be mechanistically equivalent to
integration by RAG-directed transposition.
In cultured mammalian cells integrations clearly consistent with transposition accounts for
10% [18] to 25% [19](Table 2) of integrations, but this frequency may be significantly less in
vivo. A genome wide-assessment of signal end fragment integrations [14] that occur during T
cell development identified many events consistent with the other two mechanisms described
above, but no obvious transpositions. About half of the events recovered (22/43) integrated
near a genomic RS and formed either a signal junction or a hybrid junction; in only two cases
could signal end integration be plausibly attributed to transposition (no deletion of signal end
sequence, and no non-templated additions or nearby RS). Consistent with transposition, both
examples (EL 2-4 and b108; [14]) integrated into “good” transposition targets (GC rich DNA,
with one adjacent to a G tract; see section 3.2 below). However, the presence of target site
duplications could not be verified (the other end of the integrating fragments were not
recovered). Regardless, integration by transposition is significantly less frequent for T-cell
receptor loci donors, in vivo, when compared to (for example) a transgene donor, in a
transformed pre-B cell line – 0-2/43 [14], relative to 11/44 (Table 2) (p<0.01, Fisher's exact
test).
There are many possible explanations for this difference. Defective DNA damage responses
in cultured cells may allow for abnormally long persistence of signal end intermediates [29],
and consequently more frequent transposition. RAG protein-signal end complexes assembled
at endogenous loci may be assembled differently [30], and this could make them less prone to
transposition, relative to RAG protein-signal end complexes assembled at artificial
recombination substrates. The different cell types studied (B cells/fibroblasts in cell culture,
vs. T cells in vivo) may even make unanticipated contributions. For example, TdT is active in
thymocytes in vivo but not in pre-B cells active in Igκ recombination or in fibroblasts [31]:
TdT could conceivably suppress transposition by modifying the substrate (donor 3′ termini),
or by competing with the RAGs for donor 3′ termini. An additional not-trivial issue may be
that transposition targets low complexity sequence (see 4.2, below), and these events are more
difficult to recover. In vivo studies don't allow for a cell-based cloning step, making it likely
that difficult to recover integration sites are under-represented. Finally, it must be emphasized
that the sample size of these data sets are small. The difference in frequencies, while significant,
may thus not be very large.
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3.3 The lymphoid genome – a victim of hit-and-run transposition?
The transposon associated with V(D)J recombination accumulates in cells extra-
chromosomally. It is generally assumed that this is because the RAGS perform the integration
step in cells very badly. Another possible explanation, though, is that they are much better at
excision: integration might be frequent, or at least more frequent than current estimates suggest,
but efficient re-excision/secondary recombination of the integrated transposon results in
accumulation of the extrachromosomal form. The transposon could effectively be in
equilibrium between extrachromosomal and integrated forms, with the extrachromosomal form
favored (Figure 3, i) (at least as long as RAG expression is sustained and the signals remain
intact). Excision of the recently integrated transposon can occur through a transesterification
reaction within branched integration intermediates termed disintegration [32], or after gap
repair by the more standard cleavage reaction (Figure 1).
Several arguments make “hit and run” transposition tenable as a significant mechanism. The
eventual fate of the extrachromosomal transposon fragment is usually its resolution by NHEJ
into an extrachromosomal circle. However, as long as RAG expression is sustained, the linear
form is often favored at the expense of the circle [33] primarily due to re-cleavage of the signal
junction by the “nick-nick” mechanism [34] (Figure 3, ii). Moreover, the integrated element
(however it integrates) not infrequently undergoes secondary recombination with a nearby RS
([24,35])(Table 1). Such secondary recombinations are evident only when one of the signal
end fragment's RS pairs with a nearby genomic RS (e.g. 2° in table 1, Figure 3, iii) - if both
RS of the original integrating pair directs the recombination, as might be preferred, the signal
end fragment excises and erases the evidence of the initial integration (“hit and run” integration;
Figure 3, i), as noted above.
A presumption of efficient (>90%) excision or secondary recombination means that hit-and-
run transpositions could be a major “hidden” source of near-random (see section 4.2) double
strand breaks in cells active in V(D)J recombination. Cancer-causing chromosome
abnormalities might be partly the consequence of aberrant repair of these breaks, in the same
way that hit and run transposition is effectively employed as a tool for genome mutagenesis in
fruit flies (e.g. [36]).
4 Where do they go?
A significant factor in determining the danger of a transposon to its host is its selection of target
site. In vitro, RAGs directs transposition with only loose target site preference, and this is also
apparent in cellular transpositions.
4.1 Transposition vs. other integration mechanisms
The candidate transposon can integrate by transposition, intermolecular recombination, or end
donation. A comparison of where these integrations occur according to class is sufficient to
clearly emphasize transpositions' loosely defined target site preference. Intermolecular
recombinations and end donations both show an equivalent and strong preference for
integration near a RS within an active receptor locus (∼80% in our study; Table 2, Figure 4).
Preferential targeting to receptor loci RS is also observed in the Schlissel group's study [14],
though to a lesser degree, and is consistent with very high frequencies of intermolecular
recombination targeted to specific T cell receptor RS during T cell development [21]. Notably,
aberrant resolutions of coding ends show a similar strong targeting preference (∼80%) for
actively recombining receptor loci [37].
By comparison, target sites for transpositions were significantly more widely distributed; for
example, the 11 transpositions we recovered were distributed over 8 different chromosomes
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[19] (Table 1, Figure 4). Relative to the other mechanisms, therefore, transposition is far more
likely to integrate outside DNA already active for V(D)J recombination.
4.2 Sites of predicted secondary structure are hot spots
Target sites of V(D)J recombination associated transposition in cells are generally widely
distributed, or a least more widely distributed than other reintegration mechanisms.
Nevertheless, there were two regions that might be considered “hot-spots” – both sites had two
independent transposon integrations occur near each other (Table 1, Figure 4). Two integrations
were observed 1-2kb apart in the highly repetitive Sμ region of the IgH locus. Strikingly, two
other events integrated 370 bp apart in low complexity DNA (an intron of the CXXC5 gene)
in chromosome 18. Together with an additional four events (8/11 total), these integrations
occur in regions with high potential [38] for forming a class of secondary structure termed G4
DNA (also termed G quartet, G quadruplex; reviewed in [39]); for example, 5/8 are within a
tract of 4 or more Gs. This is a higher frequency than expected by chance, even after taking
into account the known preference for targeting of transposition to GC rich DNA [5,6,20].
RAG-mediated transposition is generally directed towards secondary structures in vitro,
including hairpin tips [40,41] and bubbles [20], and targeting to G4 DNA is consistent with
these preferences. In this regard, we note we previously characterized an integration into the
center of a chromosome 5 inverted repeat as consistent with a transposition targeted to a hairpin
tip [19].
5 Concluding remarks
As yet no V(D)J recombination transposition event has been definitively linked to a lymphoid
malignancy. However, more sensitive and systematic analyses of cancer genomes (e.g. using
array-based comparative genome hybridization; aCGH) suggests the full extent of genome
instability in lymphoid malignancy is only now being appreciated [42]. It should be noted,
though, that transposition does not vary copy number and may involve relatively small-scale
(1-100 kbp) aberrations, thus may not be easily detected by either aCGH or spectral
karyotyping. Moreover, ongoing recombination (including secondary recombinations [24,35]
and excisions, or hit-and-ran transpositions - section 3.3) may obscure the contributions of
early and cancer-causing transpositions.
What is clear is that DNA elements mobilized entirely by the RAGs have disrupted a variety
of genes (HPRT, CDK6, CXXC5 - twice, ATXN7L3, and NF I/X) in cells active in V(D)J
recombination [16,19](Table 1). Evidently, transposition associated with V(D)J recombination
is a threat to the stability of lymphocyte genomes and is a potential contributor to lymphoid
malignancy. Just how much of a threat? With regard to frequency, the putative transposon
integrates into lymphocyte genomes often enough – on the order of one integration in 10,000
excisions [14,19,21]. However, less than 1/3rd (and possibly much less than 1/3rd; see 3.2
above) of these integrations can be clearly attributed to transposition [14,18,19]. The current
data sets have small sample sizes, though, making it important for future studies to more
accurately assess this frequency, particularly in in vivo settings (e.g. as in [14]). Additionally,
for a variety of reasons noted above (section 3) transposon integrations may be under-reported.
Very “loose” target site preferences, at least relative to other integration mechanisms (section
4.1), also means transposition is more likely to cause a problem when it does occur. For
example, in our unbiased study of 44 aberrant signal end integrations only 7 disrupted a non-
Ig gene, and 5 of these 7 were transpositions (Table 1).
The V(D)J recombination associated-transposon: born to be wild, and not yet fully tamed.
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V(D)J recombination. RAG1 and RAG2 direct chromosomal breakage at receptor gene loci.
Nonhomologous end joining (NHEJ) resolves chromosome breaks to assemble a mature
receptor gene (immunoglobulin or T cell receptor) and deleted extrachromosomal circle.
Yellow rectangles denote receptor-coding DNA, and triangles denote recombination signals
(RS).
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Mechanisms for integration of the excised signal end fragment/putative transposon. Blue and
black lines distinguish the putative transposon from its target site, and triangles denote
recombination signals (RS). RAG-bound signal end complexes are noted by red oval. The
features that distinguish the products of each mechanism from the others are noted at right. (A)
Transposition. Gap repair to generate the flanking target site duplication is noted by arrows.
(B) Intermolecular recombination (recombination in trans). (C) End donation (capture by an
independently generated double strand break).
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Hit-and-run Transposition. High RAG-mediated cleavage activity may keep the transposon
mostly extrachromosomal (i), consistent with accumulation of linear fragment at the expense
of circle (ii) and observed secondary recombinations after integration (iii).
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Location of integrations mapped onto a mouse chromosome idiogram
(http://www.pathology.washington.edu/research/cytopages/ideograms/mouse). Integrations
are classified as in Figure 3 and Tables 1, 2.
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Table 1
Chr1 12RS flank2 Δ 12/233 23RS flank2 Notes4
5 3344948 0/0 3344952 Tnp, cdk6, [10]
4 149422359 0/0 149,422,356 Tnp, [10]
18 35990339 0/0 35990343 Tnp, cxxc5, G4, [10]
16 32914397 0/0 32,914,394 Tnp, G4, [10]
12 114663356 0/0 114,663,359 Tnp, Sμ, G4, [10]
12 1146621245 0/0 1146621245 Tnp, Sμ, G4, [10]
5 66248447 0/0 66248455 Tnp, inv. rep., [10]
11 102157220 0/0 102157216 Tnp, atxn7L3, G4,
18 35989974 0/0 35989971 Tnp, cxxc5, G4
8 87230852 0/0 87230848 Tnp, nfix, G4
15 96473384 0/0 96473380 Tnp, G4
6 Vk4-69 CE (2) 0/0 Vk4-69 SE (0) IR, Igκ, [10]
12 VH7183.33 SE (0) 0/0 VH7183.22 CE (1) IR, IgH, [10]
12 VH15B SE (0) 0/6 JH3 CE (2) IR, 2°, IgH, [10]
4 44719680 SE (0) 0/5 44719677 CE (2) IR, pax5
18 5378614 SE (0) 0/17 5378609 CE (4) IR
6 Vκ ai4 SE (0) 0/0 Vκ ai4 CE (1) IR, Igκ
6 Vκ at4 SE (0) 0/0 Vκ kj4 SE (0) IR, 2°, Igκ
6 Vκ af4 CE (4) 0/0 Vκ af4 SE (0) IR, Igκ
6 Vκ am4 CE (2) 0/0 Vκ am4 SE (0) IR, Igκ
6 Jκ1 SE (0) 0/7 Jκ1 CE (4) IR, lgκ
6 Vκ gj38c CE (4) 5/0 Vκ gj38c SE (0) IR, Igκ
6 Vκ 4-51 CE (2) 2/0 Vκ 4-51 SE (0) IR, Igκ
6 Vκ gj38c CE (1) 0/0 Vκ cf9 SE (0) IR, 2°, lgκ
6 Vκ fl12 CE (0) 0/4 Vκ fl12 SE (0) IR, Igκ
6 Vκ 12-44 CE (3) 5/0 Vκ 12-44 SE (0) IR, Igκ
7 87352466 0/0 (MMLV) 5 ED, sema4b, [10]
19 41086374 2/0 (MMLV)5 ED, [10]
11 87565207 0/4 87565197 ED, [10]
19 4155742 25/16 4155825 ED, [10]
6 Vκ 19-25 CE (4) 0/0 Jκ2 CE (5) ED, Igκ, [10]
6 Vκ 4-50 CE (5) 0/2 Jκ5 CE (3) ED, Igκ, [10]
6 69581317 CE (1) 0/0 Vκ 4-51 CE (10) ED, Igκ, [10]
6 Jκ1 CE (4) 0/0 Vκ 8-27 CE (4) ED, Igκ, [10]
6 Vκ 4-73 CE (15) 1/0 Vκ 4-73 SE (1.3κb) ED, Igκ, [10]
6 Jκ4 CE (6) 47/59 Vκ 4-70 CE (3) ED, Igκ, [10]
6 Vκ 19-32 SE (38) 24/76 Vκ 8-27 CE (55) ED, Igκ
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Chr1 12RS flank2 Δ 12/233 23RS flank2 Notes4
6 Vκ aj4 CE (4) 0/2 Vκ ah4 CE (38) ED, Igκ
6 Vκ by9 CE (1) 0/0 Vκ gj38c CE (3) ED, Igκ
6 Vκ cq1 CE (3) 9/31 Vκ gj38c (83) ED, Igκ
6 Jκ1 CE (4) 0/0 Vκ af4 CE (3) ED, Igκ
6 70673884 0/5 Vκ 8-27 CE (4) ED, Igκ
16 Vλ1 CE (6) 0/24 No flank ED, Igλ
6 No flank 68/0 Vκ ko4 CE (1) ED, Igκ
1
Chromosome where integration occurred.
2
Genomic DNA flanking integrating element is noted relative to Ig gene segment (CE, coding end; SE, signal end; deleted nucleotides from end in
parentheses) or UCSC genome browser position (mm9 assembly).
3
Deletion(s) from 12RS or 23 RS ends of integrating fragment.
4
Integrations classed as transposition (Tnp), intermolecular recombination (IR), or end donation (ED) as in Figure 2. 2°, consistent with secondary
recombination after integration. Genes at target sites are noted in italics. G4; integration within G4 tract or site with high G4 forming potential as
determined using http://bioinformatics.ramapo.edu/QGRS/index.php [26]. Previously characterized integrations described in [10].
5
Flank could not be unambiguously assigned.
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Table 2
Integrations from Table 1 classified by integration mechanism. Total; number for each class of integration, with
% of the total integrations in parenthesis. Near Ig RS; the total number of integrations for each class near (typically
within 100 bp) of an immunoglobulin locus recombination signal, with the % of near Ig/total integrations for that
class in parenthesis.
Total (%) Near Ig RS (%)
Transposition 11 (25) 0 (0)
Intermolecular recombinations 15 (34) 12 (80)
End donations 18 (41) 14 (78)
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